Obesity therapy Saxenda lands in 10 general hospitals including Seoul National University Hospital

Published: 2018-05-24 16:26:00
Updated: 2018-05-24 10:59:51

Novo Nordisk Korea(CEO Rana Azfar Zafar) announced on the 21st that ‘Saxenda® (generic name: liraglutide 3.0mg),’ the world’s first and only GLP-1(Glucagon-Like Peptide 1) analogue for the treatment of obesity, will be extensively landing into 10 general hospitals including Seoul National Univers...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.